The Value of the C-Reactive Protein-to-Lymphocyte Ratio for Predicting Lymphovascular Invasion Based on Nutritional Status in Gastric Cancer

Rui Xu, MS1, Shuomeng Xiao, MS1, Zhi Ding, BS1, and Ping Zhao, BS1

Abstract
Preoperative nutrition and inflammation are closely related to tumors (T). Many hematological marker assessment tools comprise nutritional and systemic inflammatory indexes, evaluating essential factors for cancer nutrition, growth, and progression. This study retrospectively investigated whether the C-reactive protein (CRP)-to-lymphocyte ratio (CLR) could predict lymphovascular invasion (LVI) in gastric cancer (GC) patients based on their nutritional status. We included 262 patients who underwent GC surgery between 2019 and 2020. The patient’s nutritional status was assessed using the Patient-Generated Subjective Global Assessment (PG-SCA), and patients with scores ≥4 were classified as malnourished. First, we examined 7 hematological marker combinations using receiver operating characteristic (ROC) curves to determine which one best predicted malnutrition. The CLR predicted malnutrition more accurately than other ratios (area under the curve: 0.62, 95% confidence interval [CI]: 0.55-0.69, P = .002); the optimal cut-off value for malnutrition was 1.04. Next, we evaluated the relationship between the 7 combinations and postoperative LVI. A CLR higher than 1.04 (odds ratio [OR]: 1.81, 95% CI: 1.09-3.00, P = .021) and a platelet-to-lymphocyte ratio (PLR) higher than 129.00 (OR: 1.64, 95% CI: 1.00-2.67, P = .049) were associated with LVI in the univariate analysis, and the CLR was an independent predictor of LVI in the multivariate analysis (OR: 1.73, 95% CI: 1.04-2.87, P = .036). The preoperative CLR can assess nutritional status and independently predict LVI in GC.

Keywords
inflammation mediators, preoperative care, stomach neoplasms, nutritional assessment, hematologic tests

Abbreviations
Alb, albumin; CAR, C-reactive protein-to-albumin ratio; CI, confidence interval; CLR, C-reactive protein-to-lymphocyte ratio; CRP, C-reactive protein; GC, gastric cancer; HALP, hemoglobin, albumin, lymphocyte, and platelet; LVI, lymphovascular invasion; N, node; NAR, neutrophil-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PAR, platelet-to-albumin ratio; PG-SGA, Patient-Generated Subjective Global Assessment; PLR, platelet-to-lymphocyte ratio; PNI, perineural invasion; ROC, receiver operating characteristic; T, tumor; TNM, tumor, node, metastasis

Received: November 23, 2021; Revised: March 23, 2022; Accepted: May 19, 2022.

Introduction
Gastric cancer (GC) is the fifth most diagnosed cancer and the third leading cause of cancer deaths worldwide.1 Patients with GC often suffer from malnutrition, which is associated with age, tumor location, tumor (T) and node (N) stages, and the overall tumor, node, metastasis (TNM) stage.2-4 A patient’s nutritional status is also associated with the T stage, postoperative complications, and gastrointestinal cancer.5-7 The TNM system is a prognostic indicator to guide clinical treatment. In addition, lymphovascular invasion (LVI) is a GC prognostic indicator, identifying GC with high recurrence risk.8 Thus,

1 Sichuan Cancer Hospital, Chengdu, Sichuan, PR. China

Corresponding Author:
Rui Xu, Department of Gastrointestinal Surgery, Sichuan Cancer Hospital, 55, South 4th Section, Renmin Road, Chengdu, Sichuan 610041, PR. China.
Email: 1105331290@qq.com
accurate LVI evaluations are critical, especially before surgery. However, preoperative evaluations are challenging.

A patient’s nutritional status and the inflammatory response to cancer have been widely studied. Malnutrition correlates with immune suppression and systemic inflammation. However, it is unclear if inflammation is a cause or result of cancer; in other words, does cancer itself or the anticancer treatment induce inflammation? Regardless, inflammation affects tumor recurrence, progression, and metastasis. Several combinations of hematological markers comprising nutritional and systemic inflammatory indexes have been developed, such as the hemoglobin, albumin, lymphocyte, and platelet (HALP) combination. Many studies have explored their preoperative prognostic value for various cancers, including GC. Other hematological marker combinations include the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the C-reactive protein (CRP)-to-lymphocyte ratio (CLR), the CRP-to-albumin ratio (CAR), the platelet-to-albumin ratio (PAR), and the neutrophil-to-albumin ratio (NAR). Several markers have also been correlated with the T stage and peritoneal metastasis. However, preoperative evaluations are challenging.

This study retrospectively investigated patients with GC to determine if the CLR could predict LVI based on the nutritional status.

Materials and Methods

We retrospectively identified patients with GC who underwent curative gastrectomy in our hospital between January 2019 and January 2020. We excluded patients suffering from other malignancies, autoimmune diseases, chronic renal disease, thyroid disorders, and infectious diseases. The postoperative pathology was determined based on the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control Staging System. This study followed relevant Equator guidelines. All participants provided written informed consent, and an independent ethics committee approved the study.

We used the Patient-Generated Subjective Global Assessment (PG-SGA) to determine each patient’s nutritional status. Patients were classified as malnourished if the PG-SGA score was ≥4. Before surgery, peripheral blood was collected to analyze hemoglobin, albumin (Alb), lymphocyte, platelet, neutrophil, and CRP levels. We examined the following hematological marker combinations: HALP, NLR, PLR, CLR, CAR, PAR, and NAR. HALP was calculated as: [the hemoglobin level (g/L) × the Alb level (g/L) × the lymphocyte count (/L) × the platelet count (/L)]. NLR was calculated as the neutrophil count (/L) divided by the lymphocyte count (/L), PLR was calculated as the platelet count (/L) divided by the lymphocyte count (/L), and CLR was calculated as the CRP level (mg/L) divided by the lymphocyte count (/L). Furthermore, CAR was calculated as the CRP level (mg/L) divided by the Alb level (g/L), PAR was calculated as the platelet count (/L) divided by the Alb level (g/L), and NAR was calculated as the neutrophil count (/L) divided by the Alb level (g/L). LVI was defined as tumor cell invasion into the vascular wall or tumor emboli in the vascular endothelium. Hematoxylin and eosin staining was performed to evaluate venous invasion.

Immunohistochemistry staining for D2-0 was performed using a mouse monoclonal antibody against human lymphatic endothelium antigen to evaluate lymphatic invasion. For this study, samples without lymphatic and venous invasion were classified as LVI negative, and samples with lymphatic or venous invasion were classified as LVI positive.

Statistical analyses were performed using SPSS 20.0 software (IBM Corp.). The Youden index was calculated using a receiver operating characteristic (ROC) analysis to determine the optimal cut-off for preoperative inflammatory markers in malnutrition analyses. The Mann–Whitney U test was used to evaluate the age differences between the groups. The chi-square test was used to analyze the categorized data. We performed univariate analyses using gender, HALP, NLR, PLR, CAR, PAR, NAR, CLR, the Alb level (≤39.93 g/L or >39.93), the platelet count (>199.60 × 10^9/L or ≤199.60 × 10^9/L), and the neutrophil count (>3.50 × 10^9/L or ≤3.50 × 10^9/L). The multivariate logistic regression analysis included significant variables (P <.05) from the univariate analyses. A two-sided P value of <.05 was considered statistically significant.

Results

Clinicopathological Characteristics

Table 1 details the patient’s clinical characteristics. We enrolled 262 patients who underwent resection for GC; 188 were men, and 74 were women. The median age was 61.5 (range: 26-80) years, and 171 patients were malnourished. The wall invasion depth of the tumor was pathologically assessed as T1, T2, T3, and T4 in 49 (18.7%), 32 (12.2%), 18 (6.9%), and 163 (62.2%) patients, respectively. Furthermore, 173 patients had a positive nodal status (66.0%).

| Features                          | n = 262 |
|----------------------------------|---------|
| Age [year, median (range)]       | 61.5 (26-80) |
| Gender, n(%)                     |         |
| Male                             | 188 (71.8) |
| Female                           | 74 (28.2)  |
| Nutritional status, n(%)         |         |
| Malnourished (PG-SGA score ≥4)   | 171 (65.3) |
| Not malnourished (PG-SGA score <4)| 91 (34.7)  |
| Open surgery type, n(%)          |         |
| Total gastrectomy                | 109 (41.6) |
| Distal gastrectomy               | 135 (51.5) |
| Proximal gastrectomy             | 18 (6.9)  |
| Tumor (T) stage, n(%)            |         |
| T1                               | 49 (18.7)  |
| T2                               | 32 (12.2)  |
| T3                               | 18 (6.9)   |
| T4                               | 163 (62.2) |
| Node (N) stage, n(%)             |         |
| N0                               | 89 (34.0)  |
| N1                               | 63 (24.0)  |
| N2                               | 53 (20.2)  |
| N3                               | 57 (21.8)  |

Abbreviation: PG-SGA, patient-generated subjective global assessment.
Hematological Markers for Malnutrition

Table 2 presents the ROC analysis results for the hematological marker combinations. HALP ($P = .001$), PLR ($P = .027$), CAR ($P = .003$), and CLR ($P = .002$) were accurate malnutrition assessment tools. However, CLR more accurately assessed malnutrition than the other markers (area under the curve: 0.62, 95% confidence interval [CI]: 0.55-0.69; Figure 1). The CLR cut-off value was 1.04, and the sensitivity and specificity were 70.8% and 56.0%, respectively, for predicting malnutrition when the value was above the cut-off.

Relationships Between CLR and Clinical Features

In total, 161 patients (121 men and 40 women) had a high CLR value (CLR >1.04). The CAR value ($P = .000$), T stage ($P = .050$), and LVI ($P = .021$) significantly differed between the high and low CLR groups (Table 3).

A High CLR Value is Associated with LVI

Table 4 presents the results of the univariate and multivariate logistic regression analyses for LVI predictors. The univariate analysis identified a PLR value of >129.00 (odds ratio [OR]: 1.64, 95% CI: 1.00-2.67, $P = .049$) and a CLR value of >1.04 (OR: 1.81, 95% CI: 1.09-3.00, $P = .021$) as significant variables. The multivariate analysis identified a CLR value >1.04

---

**Table 2.** Receiver Operating Characteristic (ROC) Curve Analyses of Hematological Marker Combinations.

| Test     | AUC   | 95% confidence interval (CI) | $P$ value |
|----------|-------|------------------------------|-----------|
| HALP     | 0.37  | 0.30 to 0.44                 | .001      |
| NLR      | 0.54  | 0.46 to 0.61                 | .348      |
| PLR      | 0.58  | 0.51 to 0.66                 | .027      |
| CAR      | 0.61  | 0.54 to 0.68                 | .003      |
| CLR      | 0.62  | 0.55 to 0.69                 | .002      |
| PAR      | 0.56  | 0.49 to 0.63                 | .106      |
| NAR      | 0.51  | 0.44 to 0.59                 | .701      |

Abbreviations: AUC, area under the curve; CAR, C-reactive protein-to-albumin ratio; CLR, C-reactive protein-to-lymphocyte ratio; HALP, hemoglobin, albumin, lymphocyte, and platelet; NAR, neutrophil-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; PAR, platelet-to-albumin ratio; PLR, platelet-to-lymphocyte ratio.

Figure 1. Receiver operating characteristic (ROC) curves for malnutrition using 7 hematological marker combinations.
Previous studies have found significant correlations between CLR and the nutritional status. Okugawa Y et al. investigated correlations between CLR and various nutritional markers in 551 GC patients who underwent gastrectomy. They reported that the preoperative CLR value positively correlated with preoperative perineural invasion (PNI) and the Alb level with high collinearity (PNI: $P < .001$, $R = 0.31$; Alb: $P < .001$, $R = 0.55$). Our study found a significant association between the CLR value and the nutritional status, but the sensitivity was 70.8%, and the specificity was 56.0%. This result could be because the combination marker only includes 1 nutritional index, which is not an overall reflection of the body’s nutritional status. However, some studies suggest a close relationship between inflammation and nutritional status. We found that the optimal CLR cut-off value for malnutrition was 1.04.

The lymphocyte count is used as a nutritional evaluation index in the clinic. Leandro-Merhi et al. reported associations between the total lymphocyte count and nutritional risk and triceps skinfold thickness by multiple linear regression analyses. Numerous studies have also confirmed that quality preoperative nutrition significantly improves the nutritional and immune status, reducing postoperative complications and accelerating recovery.

The combinational markers comprise the systemic inflammatory and nutritional indexes, expanding the breadth but weakening the depth of the nutritional status. Therefore, we selected novel combinational markers based on the nutritional status. The CLR value is not the best predictor of malnutrition, but it can provide clinical guidance. Therefore, CLR may be useful to preliminarily identify malnutrition and guide nutritional intervention.

CLR, calculated as the CRP level divided by the lymphocyte count, is significantly related to prognosis in digestive cancers. Inflammation was classified as a hallmark of cancer in 2011. Thus, cancer-related inflammation affects tumor cell proliferation, invasion, and metastasis. CRP secreted from the liver is a positive acute-phase protein, and the CRP level is also associated with the systemic inflammatory response level. The CRP level is also associated with the TNM stage and tumor recurrence.28 Moreover, lymphocytes play an essential role in the host’s cytotoxic immune response. Some studies found that the lymphocyte count was significantly associated with the T stage in GC ($P = .032$). Angin et al. showed that the CLR value in stage T4 was higher than in other stages ($P = .025$). A significant negative relationship was also found between CLR and the N stage ($R = -0.500$, $P < .001$). Okugawa et al. reported a significant association between high preoperative CLR and an advanced T stage, venous invasion, and lymphatic vessel invasion. We developed a CLR that represented the nutritional, systemic inflammation, and immunological response statuses. In our study, patients with a high CLR value had LVI ($P = .021$), but the T stage, N stage, tumor location, PNI, and postoperative complications did not differ between the groups with high and low CLR values (Table 3).

LVI is when tumor cells invade the lymphatic vessel or vascular wall and is an important way for tumor cells to spread.30

### Discussion

Malnutrition and an increased inflammatory response are common in patients with GC. Therefore, malnutrition and inflammatory response markers are recommended for predicting the T stage, metastasis, and prognosis.10 Furthermore, hematological marker combinations represent a patient’s nutritional status and inflammatory condition. This study retrospectively constructed a pathological model based on malnutrition using 7 inflammatory marker combinations, including HALP, NLR, PLR, CAR, PAR, CLR, and NAR. We found that CLR was the most accurate ratio for predicting malnutrition (Table 2).

### Table 3. Clinicopathological Characteristic Comparisons Based on the C-Reactive Protein-to-Lymphocyte Ratio (CLR).

| Variable | CLR $>1.04$ | CLR $\leq 1.04$ | $P$ value |
|----------|-------------|----------------|----------|
| Age [year, median(range)] | 61 (30-80) | 62 (26-80) | .774 |
| Gender(n) | 121 | 67 | .123 |
| NLR (n) | 80 | 38 | .056 |
| CAR (n) | 158 | 15 | .000* |
| Tumor (T) location (n) | 50 | 27 | .159 |
| T1 | 27 | 22 | .050* |
| N0 | 47 | 42 | .223 |
| LVI (n) | 89 | 41 | .021* |
| PNI (n) | 72 | 60 | .125 |
| Complications (n) | 72 | 55 | .401 |
| Pneumonia | 14 | 12 | .500 |
| Abdominal infection | 7 | 5 | 1.000 |
| Lymphorrhagia | 1 | 1 | 1.000 |
| Anastomotic leakage | 3 | 2 | 1.000 |

*Indicates statistical significance (chi-squared test).

Abbreviations: CAR, C-reactive protein-to-albumin ratio; HALP, hemoglobin, albumin, lymphocyte, and platelet; NAR, neutrophil-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; LVI, lymphovascular invasion; PAR, platelet-to-albumin ratio; PLR, platelet-to-lymphocyte ratio; PNI, perineural invasion.

as an independent predictor for LVI (OR: 1.73, 95% CI: 1.04-2.87, $P = .036$).
LVI was an independent factor for the resectable GC prognosis, especially for patients with stage N0.31 LVI was also an effective predictor of lymph node metastasis.32 A previous study suggested that patients with LVI should receive adjuvant chemotherapy.33 Thus, an accurate assessment of LVI is critical. Generally, LVI is confirmed by postoperative pathological examination, and it is difficult to know the LVI status preoperatively. However, we found that the CLR value increased with LVI and identified a cut-off value of 1.04.

We also found that the CLR was an independent predictor for LVI (Table 4). Although the predictive ability of the CLR value was not high in this study, the results still indicate that the nutritional status and inflammatory reaction are closely related to LVI.

This study had a few limitations. First, some biases exist because of the retrospective nature of this study. Second, we enrolled a small No. of patients from a single institution. Third, we established this model based on malnutrition, and 1.04 may not be the ideal cut-off CLR value for predicting LVI.

**Conclusions**

The preoperative CLR value based on the patient’s nutritional status may be a helpful predictor for LVI in patients with GC.

### Acknowledgments

The present study was supported by the Sichuan Provincial Science and Technology Project (grant No. 2018SZ0263).

### Author’s Contribution

Rui Xu and Zhi Ding designed the study. Shuo-meng Xiao and Ping Zhao collected and analyzed data. Rui Xu wrote, reviewed, and edited the manuscript. All authors gave final approval of the manuscript.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### Ethics Approval and Consent to Participate

All methods were performed following the relevant guidelines and regulations. The independent Ethics Committee of Sichuan cancer hospital reviewed and approved this study (SCCHEC-02-2018-048). The independent Ethics Committee of Sichuan cancer hospital also approved the requirement for informed consent.

---

**Table 4.** Univariate and Multivariate Logistic Regression Analyses for Lymphovascular Invasion (LVI) Predictors.

| Variables | n   | OR   | 95% CI       | P value | OR   | 95% CI       | P value |
|-----------|-----|------|--------------|---------|------|--------------|---------|
| Gender    |     |      |              |         |      |              |         |
| Male      | 188 | 1    |              |         |      |              |         |
| Female    | 74  | 1.09 | 0.41 to 1.20 | .560    |      |              |         |
| NLR ≤2.17 | 144 | 1    |              |         |      |              |         |
| >2.17     | 118 | 1.32 | 0.81 to 2.14 | .269    |      |              |         |
| PLR ≤129.00 | 141 | 1    |              |         |      |              |         |
| >129.00   | 121 | 1.64 | 1.00 to 2.67 | .049*   | 1.55 | 0.94 to 2.54 | .085    |
| CAR ≤0.04 | 89  | 1    |              |         |      |              |         |
| >0.04     | 173 | 1.52 | 0.91 to 2.55 | .109    |      |              |         |
| PAR ≤4.97 | 143 | 1    |              |         |      |              |         |
| >4.97     | 119 | 1.44 | 0.89 to 2.35 | .14     |      |              |         |
| NAR ≤0.09 | 166 | 1    |              |         |      |              |         |
| >0.09     | 96  | 1.33 | 0.81 to 2.21 | .263    |      |              |         |
| CLR ≤1.04 | 101 | 1    |              |         |      |              |         |
| >1.04     | 161 | 1.81 | 1.09 to 3.00 | .021*   | 1.73 | 1.04 to 2.87 | .036*   |
| Alb ≤39.93 (g/L) | 128 | 0.76 | 1.03 to 2.75 | .121    |      |              |         |
| Plt >199.60 (10^9/L) | 116 | 1.32 | 0.81 to 2.15 | .269    |      |              |         |
| Neut >3.50 (10^9/L) | 103 | 0.94 | 0.69 to 1.85 | .692    |      |              |         |

*Indicates statistical significance.

Abbreviations: Alb, albumin; CI, confidence interval; CAR, C-reactive protein-to-albumin ratio; CLR, C-reactive protein-to-lymphocyte ratio; HALP, hemoglobin, albumin, lymphocyte, and platelet; Neut, neutrophil; NAR, neutrophil-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PAR, platelet-to-albumin ratio; PLR, platelet-to-lymphocyte ratio; Plt, platelet.
Availability of Data and Materials
The clinical datasets supporting this article’s results are available from the corresponding author upon reasonable request.

ORCID iD
Rui Xu https://orcid.org/0000-0002-6506-2400

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

2. Wie GA, Cho YA, Kim SY, Kim SM, Bae JM, Joung H. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. *Nutrition*. 2010;26(3):263-268. https://doi.org/10.1016/j.nut.2009.04.013

3. Suzuki S, Kanaji S, Yamamoto M, Oshikiri T, Nakamura T, Kakeji Y. Controlling nutritional status (conut) score predicts outcomes of curative resection for gastric cancer in the elderly. *World J Surg*. 2019;43(4):1076-1084. https://doi.org/10.1007/s00268-018-4889-6

4. Hirahara N, Tajima Y, Fujii Y, et al. Preoperative prognostic nutritional index predicts long-term outcome in gastric cancer: a propensity score-matched analysis. *Anticancer Res*. 2018;38(8):4735-4746. https://doi.org/10.21873/anticanres.12781

5. Fujiya K, Kawamura T, Omae K, et al. Impact of malnutrition after gastrectomy for gastric cancer on long-term survival. *Ann Surg Oncol*. 2018;25(4):974-983. doi:10.1245/s10434-018-6342-8

6. Fukuda Y, Yamamoto K, Hirao M, et al. Prevalence of malnutrition after gastrectomy for gastric cancer patients undergoing gastrectomy and optimal preoperative nutritional support for preventing surgical site infections. *Ann Surg Oncol*. 2015;22(3):777-785. https://doi.org/10.1245/s10434-015-4820-9

7. Zhao B, Zhang J, Zhang J, et al. The impact of preoperative underweight status on postoperative complication and survival outcome of gastric cancer patients: a systematic review and meta-analysis. *Nutr Cancer*. 2018;70(8):1254-1263. doi: 10.1080/01635581.2018.1559937

8. Kim JH, Park SS, Park SH, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer. *J Surg Res*. 2010;162(2):177-183. https://doi.org/10.1016/j.jss.2009.07.015

9. Hensler T, Hecker H, Heeg K, et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. * Infect Immun*. 1997;65(6):2283-2291. https://doi.org/10.1128/iai.65.6.2283-2291.1997

10. Guner A, Kim HI. Biomarkers for evaluating the inflammation status in patients with cancer. *J Gastric Cancer*. 2019;19(3):254-277. https://doi.org/10.5230/jgc.2019.19.e29

11. Xu SS, Li S, Xu HX, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. *World J Gastroenterol*. 2020;26(8):828-838.

12. Liu C, Li X. Stage-dependent changes in albumin, nlr, plr, and afr are correlated with shorter survival in patients with gastric cancer. *Clin Lab*. 2019;65(9):1623-1633. 10.7754/ClinLab.2019.190132. https://doi.org/10.3748/wjg.v26.i8.828

13. Chen L, Hao Y, Cong X, et al. Peripheral venous blood platelet-to-lymphocyte ratio (plr) for predicting the survival of patients with gastric cancer treated with oxo or xelox regimen neo-adjuvant chemotherapy. *Technol Cancer Res Treat*. 2019;18(1):1533033819829485. https://doi.org/10.1177/1533033819829485

14. Kono Y, Saito H, Murakami Y, et al. Postoperative ratio of the maximum C-reactive protein level to the minimum peripheral lymphocyte count as a prognostic indicator for gastric cancer patients. *Surg Today*. 2019;49(3):206-213. https://doi.org/10.1007/s00595-018-1724-x

15. Yang X, Song X, Zhang L, Wu C. Prognostic role of the pretreatment C-reactive protein/albumin ratio in gastric cancer: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99(10):e19362. https://doi.org/10.1097/MD.0000000000019362

16. Li C, Peng W, Zhang XY, Wen TF, Chen LP. The preoperative platelet to albumin ratio predicts the prognosis of hepatocellular carcinoma patients without portal hypertension after liver resection. *Medicine (Baltimore)*. 2019;88(45):e17920. https://doi.org/10.1097/MD.0000000000017920

17. Tingle SJ, Severs GR, Goodfellow M, Moir JA, White SA. NARCA: a novel prognostic scoring system using neutrophil/albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. *J Surg Oncol*. 2018;118(4):680-686. https://doi.org/10.1002/jso.25209

18. Aizawa M, Gotobuda N, Takahashi S, Konishi M, Kinoshita T. Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. *World J Surg*. 2011;35(12):2717-2722. https://doi.org/10.1007/s00268-011-1269-2

19. Nakayama Y, Gotobuda N, Shibasaki H, Nomura S, Kinoshita T, Hayashi R. Usefulness of the neutrophil/lymphocyte ratio measured preoperatively as a predictor of peritoneal metastasis in patients with advanced gastric cancer. *Surg Today*. 2014;44(11):2146-2152. https://doi.org/10.1007/s00595-014-0917-1

20. Ji X, Bu ZD, Yan Y, et al. The 8th edition of the American joint committee on cancer tumor-node-metastasis staging system for gastric cancer is superior to the 7th edition: results from a Chinese mono-institutional study of 1663 patients. *Gastric Cancer*. 2018;21(4):643-652. https://doi.org/10.1007/s10120-017-0779-5

21. van Elm E, Altman DG, Egger M, et al. The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007;147(8):573-577.

22. Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. *Oncotarget*. 2015;6(38):41370-41382. https://doi.org/10.18632/oncotarget.6269

23. Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. *Clin Nutr*. 2020;39(4):1209-1217. https://doi.org/10.1016/j.clnu.2019.05.009
24. Leandro-Merhi VA, Bráz VN, Aquino JL. Is total lymphocyte count related to nutritional markers in hospitalized older adults? *Arq Gastroenterol.* 2017;54(1):79-82. https://doi.org/10.1590/S0004-2803.2017v54n1-16

25. Fan Z, Luo G, Gong Y, et al. Prognostic value of the c-reactive protein/lymphocyte ratio in pancreatic cancer. *Ann Surg Oncol.* 2020;27(10):4017-4025. https://doi.org/10.1245/s10434-020-08301-3

26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144(5):646-674. https://doi.org/10.1016/j.cell.2011.02.013

27. Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-c-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. *Ann Surg.* 2019;272(2):342-351. https://doi.org/10.1097/SLA.0000000000003239

28. Yu Q, Yu XF, Zhang SD, Wang HH, Wang HY, Teng LS. Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. *Asian Pac J Cancer Prev.* 2013;14(10):5735-5740. https://doi.org/10.7314/APJCP.2013.14.10.5735

29. Angin YS, Yildirim M, Dasiran F, et al. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer? *ANZ J Surg.* 2021;91(7-8):1521-1527. https://doi.org/10.1111/ans.16913

30. Mei D, Zhao B, Zhang J, et al. Impact of lymphovascular invasion on survival outcome in patients with gastric cancer. *Am J Clin Pathol.* 2020;153(6):833-841. https://doi.org/10.1093/ajcp/aqaa021

31. Lu J, Dai Y, Xie JW, et al. Combination of lymphovascular invasion and the AJCC TNM staging system improves prediction of prognosis in N0 stage gastric cancer: results from a high-volume institution. *BMC Cancer.* 2019;19(1):216. https://doi.org/10.1186/s12885-019-5416-8

32. Zhang CD, Ning FL, Zeng XT, Dai DQ. Lymphovascular invasion as a predictor for lymph node metastasis and a prognostic factor in gastric cancer patients under 70 years of age: a retrospective analysis. *Int J Surg.* 2018;53(3):214-220. https://doi.org/10.1016/j.ijsu.2018.03.073

33. Du C, Zhou Y, Huang K, Zhao G, Fu H, Shi Y. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. *J Gastrointest Surg.* 2011;15(12):2153-2158. https://doi.org/10.1007/s11605-011-1684-6